symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
FNCH,4.3,0.215926,8906,6900468,0,4.19-49.65,-0.09,"Finch Therapeutics Group, Inc.",USD,0001733257,US31773D1019,31773D101,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.finchtherapeutics.com,"Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and Crohn's disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.",Mr. Matthew P. Blischak J.D.,Healthcare,US,18,617 229 6499,200 Inner Belt Road,Somerville,MA,02143,,0,https://financialmodelingprep.com/image-stock/FNCH.png,2021-03-19,False,False,True,False,False
